Issue link: https://www.e-digitaleditions.com/i/1469783
22 June 2022 Inhalation In vitro analytical methods e nose is an attractive route for rapid drug deliv- ery, enabling access to the central nervous system and a means to bypass the blood-brain barrier, how- ever, nasal drug delivery can be challenging. Intertek Melbourn has established powerful in vitro analytical methods that drive understanding of drug delivery deposition, allowing for targeted formulation design. To accelerate your nasal drug product development, our strengths in this area are underpinned by Inter- tek's extensive analytical expertise, stability storage solutions and clinical trial manufacturing services. Intertek Melbourn UK: +44 1763 261648 bd.melbourn@intertek.com www.intertek.com Developing biologics for inhalation Nasal devices and nebulizers can be preferred deliv- ery methods for inhalable biologics. Over the last few years, there have been many new advancements in technology, techniques and test equipment. Make sure you use the proper equipment for such develop- ment to accurately and repeatably characterize your new device or drug formulation. Call us for assis- tance with any new or existing test system require- ments and recommendations. MSP, a Division of TSI US: +1 651 417-1440 mspsales@tsi.com www.mspcorp.com Smart nebulization Vectura's breath-actuated nebulizers, with guided inhalation, have been developed to improve drug delivery to the lung, with the aim of achieving bet- ter clinical outcomes and/or shortened treatment times. Smart nebulization also offers opportunities to accelerate and de-risk early-stage development, with the potential for clearer clinical end-points, more consistent drug delivery to patients, and reduction of the complexity associated with inhaled formulation development. Vectura UK: +44 1249 667700 enquiries@vectura.com www.vectura.com